U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07298421) titled 'A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease' on Dec. 19.
Brief Summary: This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).
Study Start Date: May 29, 2026
Study Type: INTERVENTIONAL
Condition:
Moderately to Severely Active Crohns Disease
Intervention:
DRUG: Afimkibart
Afimkibart will be administered as IV infusion. Afimkibart will be adm...